Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393600 · ClinicalTrials.gov registry record · Phase 2
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 2 study of Tardive Dyskinesia, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 11
- Study locations
NCT01393600 is a Phase 2 study of Tardive Dyskinesia that has completed, run by Neurocrine Biosciences. The registered enrollment target is 37 participants, below the 142-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (74% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT01393600, a Phase 2 study of Tardive Dyskinesia, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NBI-98854
Study Locations (11)
California
- Synergy Clinical Research - National City
- UCSD Outpatient Psychiatry - San Diego
- PCSD - Feighner Research - San Diego
Florida
- San Marcus Research Clinic, Inc. - Miami
- Medical Research Marseilles - Miami
- Scientific Clinical Research, Inc. - North Miami
Arkansas
- Woodland International Research Group, Inc - Little Rock
Georgia
- Atlanta Center for Medical Research - Atlanta
Missouri
- St. Louis Clinical Trials - St Louis
Texas
- Clinical Trials of Texas, Inc. - San Antonio
West Virginia
- CAMC Clinical Trials Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393600
The ClinicalTrials.gov registry entry for NCT01393600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (74% lower). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tardive Dyskinesia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01393600 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01393600 about?
NCT01393600 is a clinical study titled "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder". The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder.
What is the current status of trial NCT01393600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2011-08. Estimated completion is 2012-02.
What conditions does trial NCT01393600 study?
This clinical trial studies the following conditions: Tardive Dyskinesia.
What interventions are being tested in trial NCT01393600?
The interventions under investigation include: Placebo (DRUG), NBI-98854 (DRUG).
Who is sponsoring clinical trial NCT01393600?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01393600 being conducted?
This trial has 11 study locations across Arkansas, California, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tardive Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
RECRUITING · NA
-
Levetiracetam Treatment of Tardive Dyskinesia
COMPLETED · Phase 3
-
Addressing Involuntary Movements in Tardive Dyskinesia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.